Article

Minimizing biological risk for novel inhibitory drug targets: One knockout is all you need

2024-06-20

Abstract excerpt

We argue that biological risk for novel inhibitory drug targets can be minimized, almost eliminated, by a computational analysis of the healthcare records and DNA sequences in resources like UK Biobank or All-of-Us. The key insight is that an inhibitory drug is functionally equivalent to a loss-of-function (LOF) variant in the targeted gene. It is a special case of what has been called an “experiment of nature”. T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8e9ddf25-ddfe-5121-85e3-deb205253f37
DOI: 10.1101/2024.06.19.24309116

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Minimizing biological risk for novel inhibitory drug targets: One knockout is all you needDOI 10.1101/2024.06.19.24309116Read

Evaluating potential drug targets through human loss-of-function genetic variationSemantic proximity Read

Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.Semantic proximity Read

Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity.Semantic proximity Read

Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction.Semantic proximity Read

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read

Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygositySemantic proximity Read

Using human genetics to discover new therapeutic targets for plasma lipids.Semantic proximity Read

Common pitfalls in drug target Mendelian randomization and how to avoid them.Semantic proximity Read

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read

Drug development advances in human genetics‐based targetsSemantic proximity Read